{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:16:32Z","timestamp":1743146192627,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":51,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071625729"},{"type":"electronic","value":"9781071625736"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-2573-6_17","type":"book-chapter","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T16:06:13Z","timestamp":1662480373000},"page":"491-504","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomics of Opioid Treatment for Pain Management"],"prefix":"10.1007","author":[{"given":"Sarahbeth","family":"Howes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra R.","family":"Cloutet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaeyeon","family":"Kweon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Raza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyse M.","family":"Cornett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"17_CR1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1515\/dmpt-2016-0005","volume":"31","author":"AM Peir\u00f3","year":"2016","unstructured":"Peir\u00f3 AM, Planelles B, Juhasz G, Bagdy G, Libert F, Eschalier A, Busserolles J, Sperlagh B, Llerena A (2016) Pharmacogenomics in pain treatment. Drug Metab Pers Ther 31:131\u2013142","journal-title":"Drug Metab Pers Ther"},{"key":"17_CR2","first-page":"125","volume":"12","author":"AD Kaye","year":"2019","unstructured":"Kaye AD, Garcia AJ, Hall OM, Jeha GM, Cramer KD, Granier AL, Kallurkar A, Cornett EM, Urman RD (2019) Update on the pharmacogenomics of pain management. Pharmacogenomics Pers Med 12:125\u2013143","journal-title":"Pharmacogenomics Pers Med"},{"key":"17_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11912-020-0865-4","volume":"22","author":"EM Cornett","year":"2020","unstructured":"Cornett EM, Carroll Turpin MA, Pinner A, Thakur P, Sekaran TSG, Siddaiah H, Rivas J, Yates A, Huang GJ, Senthil A, Khurmi N, Miller JL, Stark CW, Urman RD, Kaye AD (2020) Pharmacogenomics of pain management: the impact of specific biological polymorphisms on drugs and metabolism. Curr Oncol Rep 22:18","journal-title":"Curr Oncol Rep"},{"key":"17_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1213\/ANE.0000000000000721","volume":"121","author":"N Jimenez","year":"2015","unstructured":"Jimenez N, Galinkin JL (2015) Personalizing pediatric pain medicine: using population-specific pharmacogenetics, genomics, and other \u2013 omics approaches to predict response. Anesth Analg 121:183\u2013187","journal-title":"Anesth Analg"},{"key":"17_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2147\/tcrm.2006.2.4.447","volume":"2","author":"M Mandal\u00e0","year":"2006","unstructured":"Mandal\u00e0 M, Moro C, Labianca R, Cremonesi M, Barni S (2006) Optimizing use of opiates in the management of cancer pain. Ther Clin Risk Manag 2:447\u2013453","journal-title":"Ther Clin Risk Manag"},{"key":"17_CR6","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.pmn.2007.04.001","volume":"8","author":"JA Paice","year":"2007","unstructured":"Paice JA (2007) Pharmacokinetics, pharmacodynamics, and pharmacogenomics of opioids. Pain Manag Nurs 8:S2\u2013S5","journal-title":"Pain Manag Nurs"},{"key":"17_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1196\/annals.1307.045","volume":"1025","author":"W Han","year":"2004","unstructured":"Han W, Ide S, Sora I, Yamamoto H, Ikeda K (2004) A possible genetic mechanism underlying individual and interstrain differences in opioid actions: focus on the mu opioid receptor gene. Ann N Y Acad Sci 1025:370\u2013375","journal-title":"Ann N Y Acad Sci"},{"key":"17_CR8","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/j.1399-6576.2004.00517.x","volume":"48","author":"P Klepstad","year":"2004","unstructured":"Klepstad P, Rakv\u00e5g TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F (2004) The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 48:1232\u20131239","journal-title":"Acta Anaesthesiol Scand"},{"key":"17_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/ALN.0b013e318182af21","volume":"109","author":"AT Sia","year":"2008","unstructured":"Sia AT, Lim Y, Lim ECP, Goh RWC, Law HY, Landau R, Teo Y-Y, Tan EC (2008) A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 109:520\u2013526","journal-title":"Anesthesiology"},{"key":"17_CR10","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","volume":"11","author":"AM Trescot","year":"2008","unstructured":"Trescot AM, Datta S, Lee M, Hansen H (2008) Opioid pharmacology. Pain Physician 11:S133\u2013S153","journal-title":"Pain Physician"},{"key":"17_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1523\/JNEUROSCI.4458-07.2008","volume":"28","author":"BB Land","year":"2008","unstructured":"Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C (2008) The dysphoric component of stress is encoded by activation of the Dynorphin \u03ba-opioid system. J Neurosci 28:407\u2013414","journal-title":"J Neurosci"},{"key":"17_CR12","first-page":"1704","volume":"46","author":"I Chatti","year":"2017","unstructured":"Chatti I, Woillard J-B, Mili A, Creveaux I, Ben Charfeddine I, Feki J, Langlais S, Ben Fatma L, Saad A, Gribaa M, Libert F (2017) Genetic analysis of mu and kappa opioid receptor and COMT enzyme in cancer pain Tunisian patients under opioid treatment. Iran J Public Health 46:1704\u20131711","journal-title":"Iran J Public Health"},{"key":"17_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/164_2017_32","volume":"247","author":"K Abdallah","year":"2018","unstructured":"Abdallah K, Gendron L (2018) The Delta opioid receptor in pain control. Handb Exp Pharmacol 247:147\u2013177","journal-title":"Handb Exp Pharmacol"},{"key":"17_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/FBP.0b013e32834a1f2c","volume":"22","author":"C Gav\u00e9riaux-Ruff","year":"2011","unstructured":"Gav\u00e9riaux-Ruff C, Kieffer BL (2011) Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol 22:405\u2013414","journal-title":"Behav Pharmacol"},{"key":"17_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","volume":"84","author":"HS Smith","year":"2009","unstructured":"Smith HS (2009) Opioid Metabolism. Mayo Clin Proc 84:613\u2013624","journal-title":"Mayo Clin Proc"},{"key":"17_CR16","doi-asserted-by":"crossref","unstructured":"Opioid Metabolism and Effects of Cytochrome P450 | Pain Medicine | Oxford Academic. https:\/\/academic.oup.com\/painmedicine\/article\/10\/suppl_1\/S20\/1914905?login=true. Retrieved 9 Aug 2021","DOI":"10.1111\/j.1526-4637.2009.00596.x"},{"key":"17_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.36076\/ppj.2008\/11\/237","volume":"11","author":"HS Smith","year":"2008","unstructured":"Smith HS (2008) Variations in opioid responsiveness. Pain Physician 11:237\u2013248","journal-title":"Pain Physician"},{"key":"17_CR18","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1177\/0269881120944162","volume":"34","author":"A Singh","year":"2020","unstructured":"Singh A, Zai C, Mohiuddin AG, Kennedy JL (2020) The pharmacogenetics of opioid treatment for pain management. J Psychopharmacol (Oxf) 34:1200\u20131209","journal-title":"J Psychopharmacol (Oxf)"},{"key":"17_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","volume":"48","author":"S-F Zhou","year":"2009","unstructured":"Zhou S-F (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689\u2013723","journal-title":"Clin Pharmacokinet"},{"key":"17_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/sj.tpj.6500406","volume":"7","author":"J Kirchheiner","year":"2007","unstructured":"Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J-T, L\u00f6tsch J, Roots I, Brockm\u00f6ller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257\u2013265","journal-title":"Pharmacogenomics J"},{"key":"17_CR21","doi-asserted-by":"publisher","first-page":"e1343","DOI":"10.1542\/peds.2011-2538","volume":"129","author":"LE Kelly","year":"2012","unstructured":"Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G (2012) More codeine fatalities after tonsillectomy in north American children. Pediatrics 129:e1343\u2013e1347","journal-title":"Pediatrics"},{"key":"17_CR22","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41436-018-0431-8","volume":"21","author":"DM Smith","year":"2019","unstructured":"Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH (2019) CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet Med 21:1842\u20131850","journal-title":"Genet Med"},{"key":"17_CR23","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2217\/pgs-2017-0022","volume":"18","author":"SL Koolen","year":"2017","unstructured":"Koolen SL, Van der Rijt CC (2017) Is there a role for pharmacogenetics in the dosing of fentanyl? Pharmacogenomics 18:417\u2013419","journal-title":"Pharmacogenomics"},{"key":"17_CR24","doi-asserted-by":"publisher","first-page":"414","DOI":"10.2133\/dmpk.DMPK-11-RG-134","volume":"27","author":"Y Takashina","year":"2012","unstructured":"Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J (2012) Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet 27:414\u2013421","journal-title":"Drug Metab Pharmacokinet"},{"key":"17_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/FPC.0000000000000032","volume":"24","author":"DT Barratt","year":"2014","unstructured":"Barratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL, Tuke J, Somogyi AA (2014) Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenet Genomics 24:185\u2013194","journal-title":"Pharmacogenet Genomics"},{"key":"17_CR26","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bcp.13129","volume":"83","author":"EJM Kuip","year":"2017","unstructured":"Kuip EJM, Zandvliet ML, Koolen SLW, Mathijssen RHJ, van der Rijt CCD (2017) A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients: variability in fentanyl pharmacokinetics. Br J Clin Pharmacol 83:294\u2013313","journal-title":"Br J Clin Pharmacol"},{"key":"17_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/papr.12232","volume":"15","author":"LM Nielsen","year":"2015","unstructured":"Nielsen LM, Olesen AE, Branford R, Christrup LL, Sato H, Drewes AM (2015) Association between human pain-related genotypes and variability in opioid analgesia: an updated review. Pain Pract 15:580\u2013594","journal-title":"Pain Pract"},{"key":"17_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1037\/a0013628","volume":"16","author":"A Rosenblum","year":"2008","unstructured":"Rosenblum A, Marsch LA, Joseph H, Portenoy RK (2008) Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 16:405\u2013416","journal-title":"Exp Clin Psychopharmacol"},{"key":"17_CR29","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3389\/fphar.2018.01122","volume":"9","author":"L Cardia","year":"2018","unstructured":"Cardia L, Calapai G, Quattrone D, Mondello C, Arcoraci V, Calapai F, Mannucci C, Mondello E (2018) Preclinical and clinical pharmacology of hydrocodone for chronic pain: a mini review. Front Pharmacol 9:1122","journal-title":"Front Pharmacol"},{"key":"17_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2125.2003.02002.x","volume":"57","author":"MR Hutchinson","year":"2004","unstructured":"Hutchinson MR, Menelaou A, Foster DJR, Coller JK, Somogyi AA (2004) CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 57:287\u2013297","journal-title":"Br J Clin Pharmacol"},{"key":"17_CR31","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1097\/AJP.0000000000000214","volume":"31","author":"OA Linares","year":"2015","unstructured":"Linares OA, Fudin J, Daly AL, Boston RC (2015) Individualized hydrocodone therapy based on phenotype, pharmacogenetics, and pharmacokinetic dosing. Clin J Pain 31:1026\u20131035","journal-title":"Clin J Pain"},{"key":"17_CR32","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00045391-200201000-00010","volume":"9","author":"KS Latta","year":"2002","unstructured":"Latta KS, Ginsberg B, Barkin RL (2002) Meperidine: a critical review. Am J Ther 9:53\u201368","journal-title":"Am J Ther"},{"key":"17_CR33","first-page":"930","volume":"32","author":"J Ram\u00edrez","year":"2004","unstructured":"Ram\u00edrez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ (2004) CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos Biol Fate Chem 32:930\u2013936","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"17_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/00498254.2019.1599465","volume":"50","author":"JL Murray","year":"2020","unstructured":"Murray JL, Mercer SL, Jackson KD (2020) Impact of cytochrome P450 variation on meperidine N -demethylation to the neurotoxic metabolite normeperidine. Xenobiotica 50:132\u2013145","journal-title":"Xenobiotica"},{"key":"17_CR35","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2217\/pgs-2020-0040","volume":"21","author":"S Packiasabapathy","year":"2020","unstructured":"Packiasabapathy S, Aruldhas BW, Horn N, Overholser BR, Quinney SK, Renschler JS, Sadhasivam S (2020) Pharmacogenomics of methadone: a narrative review of the literature. Pharmacogenomics 21:871\u2013887","journal-title":"Pharmacogenomics"},{"key":"17_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.pain.2009.07.013","volume":"146","author":"C Walter","year":"2009","unstructured":"Walter C, L\u00f6tsch J (2009) Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146:270\u2013275","journal-title":"Pain"},{"key":"17_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2217\/pgs.13.58","volume":"14","author":"O Levran","year":"2013","unstructured":"Levran O, Peles E, Randesi M, Shu X, Ott J, Shen P-H, Adelson M, Kreek MJ (2013) Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics 14:755\u2013768","journal-title":"Pharmacogenomics"},{"key":"17_CR38","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 41:1153\u20131193","journal-title":"Clin Pharmacokinet"},{"key":"17_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/FPC.0b013e32833947c2","volume":"20","author":"CF Thorn","year":"2010","unstructured":"Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB (2010) PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 20:520\u2013523","journal-title":"Pharmacogenet Genomics"},{"key":"17_CR40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1399-6576.2005.00772.x","volume":"49","author":"P Klepstad","year":"2005","unstructured":"Klepstad P, Dale O, Skorpen F, Borchgrevink PC, Kaasa S (2005) Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand 49:902\u2013908","journal-title":"Acta Anaesthesiol Scand"},{"key":"17_CR41","volume-title":"OxycodoneStatPearls","author":"NM Sadiq","year":"2021","unstructured":"Sadiq NM, Dice TJ, Mead T (2021) OxycodoneStatPearls. StatPearls Publishing, Treasure Island"},{"key":"17_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00228-011-1093-5","volume":"68","author":"TN Andreassen","year":"2012","unstructured":"Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstr\u00f6m S, Kaasa S, Dale O (2012) Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol 68:55\u201364","journal-title":"Eur J Clin Pharmacol"},{"key":"17_CR43","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-013-0036-0","volume":"73","author":"KC S\u00f6derberg L\u00f6fdal","year":"2013","unstructured":"S\u00f6derberg L\u00f6fdal KC, Andersson ML, Gustafsson LL (2013) Cytochrome P450-mediated changes in oxycodone pharmacokinetics\/pharmacodynamics and their clinical implications. Drugs 73:533\u2013543","journal-title":"Drugs"},{"key":"17_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","volume":"54","author":"ST Zwisler","year":"2010","unstructured":"Zwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH (2010) Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 54:232\u2013240","journal-title":"Acta Anaesthesiol Scand"},{"key":"17_CR45","unstructured":"Trevena Inc (2020) Olinvyk (oliceridine) [prescribing information]"},{"key":"17_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/bcpt.13141","volume":"124","author":"M Saiz-Rodr\u00edguez","year":"2019","unstructured":"Saiz-Rodr\u00edguez M, Ochoa D, Herrador C, Belmonte C, Rom\u00e1n M, Alday E, Koller D, Zubiaur P, Mej\u00eda G, Hern\u00e1ndez-Mart\u00ednez M, Abad-Santos F (2019) Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects. Basic Clin Pharmacol Toxicol 124:321\u2013329","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"17_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/00952990.2016.1172078","volume":"42","author":"Z Zahari","year":"2016","unstructured":"Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, Tan SC, Mohamad N, Ismail R (2016) Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse 42:587\u2013596","journal-title":"Am J Drug Alcohol Abuse"},{"key":"17_CR48","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","volume":"123","author":"ED Kharasch","year":"2015","unstructured":"Kharasch ED, Regina KJ, Blood J, Friedel C (2015) Methadone pharmacogenetics. Anesthesiology 123:1142\u20131153","journal-title":"Anesthesiology"},{"key":"17_CR49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5055\/jom.2012.0119","volume":"8","author":"S Sadhasivam","year":"2012","unstructured":"Sadhasivam S, Krekels EHJ, Chidambaran V, Esslinger HR, Ngamprasertwong P, Zhang K, Fukuda T, Vinks AA (2012) Morphine clearance in children: does race or genetics matter? J Opioid Manag 8:217\u2013226","journal-title":"J Opioid Manag"},{"key":"17_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/fcp.12128","volume":"29","author":"AE Olesen","year":"2015","unstructured":"Olesen AE, Sato H, Nielsen LM, Staahl C, Droney J, Gretton S, Branford R, Drewes AM, Arendt-Nielsen L, Riley J, Ross J (2015) The genetic influences on oxycodone response characteristics in human experimental pain. Fundam Clin Pharmacol 29:417\u2013425","journal-title":"Fundam Clin Pharmacol"},{"key":"17_CR51","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2217\/pgs-2016-0183","volume":"18","author":"R Balyan","year":"2017","unstructured":"Balyan R, Mecoli M, Venkatasubramanian R, Chidambaran V, Kamos N, Clay S, Moore DL, Mavi J, Glover CD, Szmuk P, Vinks A, Sadhasivam S (2017) CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics 18:337\u2013348","journal-title":"Pharmacogenomics"}],"container-title":["Methods in Molecular Biology","Pharmacogenomics in Drug Discovery and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-2573-6_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T16:58:22Z","timestamp":1701017902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-2573-6_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9781071625729","9781071625736"],"references-count":51,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-2573-6_17","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"7 September 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}